



Modern Approaches in Cardiovascular Disease Therapeutics: From Molecular Genetics to Tissue Engineering

Guest Editors:

Dr. Panagiotis Mallis

Department of Tissue Engineering and Regenerative Medicine of Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), 11527 Athina, Greece

Dr. Efstathios Michalopoulos

Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), Athens, Greece

Deadline for manuscript submissions:

closed (31 August 2021)

Message from the Guest Editors

Cardiovascular disease is a group of complex disorders which includes peripheral arterial disease, coronary heart disease, cerebrovascular disease and rheumatic heart disease. Each year, more than 800.000 bypass surgeries are performed. Additionally, it is speculated that more than 17 million of people are died due to CAD, which approximately represents the 31% of all deaths, worldwide.

The primary cause for the development of CAD is the atherogenesis and the developed atherosclerosis, which induces functional alterations to the vessels of the circulatory system. In this process, individual's genetic background may influence the progression of this disease. Understanding better the individual's genetic alterations, which are specific for the CAD initiation and progression, novel targets for advanced therapeutics may be revealed. Advanced approaches for CAD prevention also involve the use of suitable tissue engineered vascular grafts for bypass surgeries.

Modern approaches for CAD will consider individual's own characteristics, promoting in this way advanced personalized therapeutic strategies.

We look forward to receiving your valuable contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)